Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. (Q49123747)

From Wikidata

Jump to navigation Jump to search

scientific article published on 26 June 2011

Language	Label	Description	Also known as
English	Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.	scientific article published on 26 June 2011

Statements

scholarly article

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. (English)

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

1 reference

based on heuristic

inferred from title

10

object named as

Eric P Winer

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

1

object named as

Nancy U Lin

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

Klaudia Steplewski

6

object named as

Klaudia Steplewski

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

Denise Zembryki

8

object named as

Denise Zembryki

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

author name string

Wolfgang Eierman

2

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

Richard Greil

3

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

Mario Campone

4

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

Bella Kaufman

5

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

Stephen R Lane

7

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

Stephen D Rubin

9

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

publication date

26 June 2011

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

105

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

3

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

613-620

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

https://scigraph.springernature.com/pub.10.1007/s11060-011-0629-y

0 references

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Brain metastases: the HER2 paradigm

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival in patients with brain metastases from breast cancer: the importance of HER-2 status

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metastatic behavior of breast cancer subtypes

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Capecitabine therapy of central nervous system metastases from breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706359

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-011-0629-Y

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/21706359

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q49123747&oldid=2117180942"